NASDAQ:XLRN - Acceleron Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$37.79 +0.80 (+2.16 %)
(As of 06/20/2018 10:49 AM ET)
Previous Close$37.21
Today's Range$37.21 - $37.79
52-Week Range$29.35 - $46.93
Volume1,181 shs
Average Volume272,729 shs
Market Capitalization$1.68 billion
P/E Ratio-14.07
Dividend YieldN/A
Beta1.44
Acceleron Pharma logoAcceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XLRN
CUSIPN/A
Phone617-649-9200

Debt

Debt-to-Equity RatioN/A
Current Ratio23.21
Quick Ratio23.21

Price-To-Earnings

Trailing P/E Ratio-14.07
Forward P/E Ratio-15.88
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.48 million
Price / Sales128.34
Cash FlowN/A
Price / CashN/A
Book Value$8.07 per share
Price / Book4.68

Profitability

EPS (Most Recent Fiscal Year)($2.68)
Net Income$-108,450,000.00
Net Margins-839.98%
Return on Equity-34.52%
Return on Assets-32.40%

Miscellaneous

Employees139
Outstanding Shares45,780,000

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc (NASDAQ:XLRN) issued its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.58) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.64) by $0.06. The biopharmaceutical company earned $3.23 million during the quarter, compared to the consensus estimate of $3.77 million. Acceleron Pharma had a negative net margin of 839.98% and a negative return on equity of 34.52%. The firm's revenue was down 12.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.66) EPS. View Acceleron Pharma's Earnings History.

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Acceleron Pharma.

What price target have analysts set for XLRN?

10 Wall Street analysts have issued 12-month price targets for Acceleron Pharma's shares. Their forecasts range from $33.00 to $69.00. On average, they expect Acceleron Pharma's share price to reach $52.6250 in the next year. View Analyst Ratings for Acceleron Pharma.

What are Wall Street analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:
  • 1. Cann analysts commented, "While we have not modeled ACE-083 into our outlook for Acceleron by 2022, Fast Track designation has the potential to move the timeline for ACE-083 forward. Based on this and recently released positive results for ACE-083, we believe this program will continue to advance and will likely become a marketed drug." (5/1/2018)
  • 2. HC Wainwright analysts commented, "Preliminary ACE-083 Phase 2 Data Demonstrates Serious Gains in FSHD; Part 2 Current Underway Data demonstrates dose-dependent increases in total muscle volume. This morning, Acceleron Pharma announced preliminary results from the ongoing Phase 2 trial of ACE-083 in facioscapulohumeral muscular dystrophy (FSHD) from the 150 and 200mg arms at the American Academy of Neurology (AAN) 70th Annual Meeting, which is being held in Los Angeles. ACE-083 demonstrated dose-dependent increases in total muscle volume in both the Tibalis Anterior (TA) and Biceps Brachii (BB) muscle cohorts, with a 15-20% increase observed at the higher dose level. In addition, a decrease in fat fraction was observed in both cohorts, however, it was more notable in the TA cohort. With regard to safety, ACE-083 was safe and generally well-tolerated in subjects for up to three months, which included five doses." (4/26/2018)
  • 3. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (8/9/2017)

Who are some of Acceleron Pharma's key competitors?

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:
  • Mr. Habib J. Dable, CEO, Pres & Director (Age 49)
  • Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 75)
  • Mr. Kevin F. McLaughlin, CFO, Sr. VP & Treasurer (Age 62)
  • Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 58)
  • Dr. Matthew L. Sherman, Chief Medical Officer & Exec. VP (Age 62)

Has Acceleron Pharma been receiving favorable news coverage?

Media headlines about XLRN stock have trended somewhat positive on Wednesday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Acceleron Pharma earned a news impact score of 0.12 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.12 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Acceleron Pharma's major shareholders?

Acceleron Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.81%), Farallon Capital Management LLC (3.06%), Westfield Capital Management Co. LP (3.00%), Eagle Asset Management Inc. (2.68%), Artal Group S.A. (1.86%) and Eventide Asset Management LLC (1.16%). Company insiders that own Acceleron Pharma stock include Christopher Rovaldi, Corp /De/ Celgene, Jean George, John D Quisel, John L Knopf, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops, Steven D Ertel and Terrance Mcguire. View Institutional Ownership Trends for Acceleron Pharma.

Which major investors are selling Acceleron Pharma stock?

XLRN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Westfield Capital Management Co. LP, Eventide Asset Management LLC, American Century Companies Inc., Prudential Financial Inc., Artisan Partners Limited Partnership, Candriam Luxembourg S.C.A. and Citigroup Inc.. Company insiders that have sold Acceleron Pharma company stock in the last year include Christopher Rovaldi, Jean George, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar and Richard F Pops. View Insider Buying and Selling for Acceleron Pharma.

Which major investors are buying Acceleron Pharma stock?

XLRN stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, DekaBank Deutsche Girozentrale, Federated Investors Inc. PA, PNC Financial Services Group Inc., UBS Group AG, Artal Group S.A., Tiverton Asset Management LLC and Lord Abbett & CO. LLC. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $37.79.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $1.68 billion and generates $13.48 million in revenue each year. The biopharmaceutical company earns $-108,450,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Acceleron Pharma employs 139 workers across the globe.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]


MarketBeat Community Rating for Acceleron Pharma (XLRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  335 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  533
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.